Go Pro
→ NASA's ISS Replacement Could Go to This Tiny Space Firm (From Behind the Markets) (Ad)tc pixel Free PXMD Stock Alerts

PaxMedica (PXMD) Competitors

PaxMedica logo
$0.0005 0.00 (0.00%)
As of 09/23/2026
Compare

PXMD vs. VRPX, SYRS, TRVN, NAVB, and GNCA

Should you buy PaxMedica stock or one of its competitors? PaxMedica's main competitors and comparable companies include Virpax Pharmaceuticals (VRPX), Syros Pharmaceuticals (SYRS), Trevena (TRVN), Navidea Biopharmaceuticals (NAVB), and Genocea Biosciences (GNCA). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does PaxMedica compare to Virpax Pharmaceuticals?

PaxMedica (NASDAQ:PXMD) and Virpax Pharmaceuticals (NASDAQ:VRPX) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their media sentiment, risk, analyst recommendations, valuation, institutional ownership, profitability, earnings and dividends.

PaxMedica has a beta of -0.99, indicating that its stock price is 199% less volatile than the broader market. Comparatively, Virpax Pharmaceuticals has a beta of -16.55, indicating that its stock price is 1,755% less volatile than the broader market.

PaxMedica is trading at a lower price-to-earnings ratio than Virpax Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
PaxMedicaN/AN/A-$18.29M-$6.09N/A
Virpax PharmaceuticalsN/AN/A-$15.19M-$123.25N/A

4.9% of PaxMedica shares are owned by institutional investors. Comparatively, 32.2% of Virpax Pharmaceuticals shares are owned by institutional investors. 1.0% of PaxMedica shares are owned by company insiders. Comparatively, 3.7% of Virpax Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

In the previous week, PaxMedica's average media sentiment score of 0.00 equaled Virpax Pharmaceuticals'average media sentiment score.

Company Overall Sentiment
PaxMedica Neutral
Virpax Pharmaceuticals Neutral

Virpax Pharmaceuticals' return on equity of -1,554.34% beat PaxMedica's return on equity.

Company Net Margins Return on Equity Return on Assets
PaxMedicaN/A -3,167.89% -560.35%
Virpax Pharmaceuticals N/A -1,554.34%-338.29%

Summary

Virpax Pharmaceuticals beats PaxMedica on 5 of the 8 factors compared between the two stocks.

How does PaxMedica compare to Syros Pharmaceuticals?

Syros Pharmaceuticals (NASDAQ:SYRS) and PaxMedica (NASDAQ:PXMD) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their valuation, earnings, risk, profitability, analyst recommendations, institutional ownership, media sentiment and dividends.

PaxMedica's return on equity of -3,167.89% beat Syros Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Syros PharmaceuticalsN/A -3,369.56% -97.04%
PaxMedica N/A -3,167.89%-560.35%

Syros Pharmaceuticals has a beta of 1.31, meaning that its share price is 31% more volatile than the broader market. Comparatively, PaxMedica has a beta of -0.99, meaning that its share price is 199% less volatile than the broader market.

PaxMedica has lower revenue, but higher earnings than Syros Pharmaceuticals. Syros Pharmaceuticals is trading at a lower price-to-earnings ratio than PaxMedica, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Syros Pharmaceuticals$386K0.03-$164.57M-$3.03N/A
PaxMedicaN/AN/A-$18.29M-$6.09N/A

In the previous week, Syros Pharmaceuticals' average media sentiment score of 0.00 equaled PaxMedica'saverage media sentiment score.

Company Overall Sentiment
Syros Pharmaceuticals Neutral
PaxMedica Neutral

91.5% of Syros Pharmaceuticals shares are held by institutional investors. Comparatively, 4.9% of PaxMedica shares are held by institutional investors. 12.3% of Syros Pharmaceuticals shares are held by insiders. Comparatively, 1.0% of PaxMedica shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

Syros Pharmaceuticals beats PaxMedica on 6 of the 9 factors compared between the two stocks.

How does PaxMedica compare to Trevena?

Trevena (NASDAQ:TRVN) and PaxMedica (NASDAQ:PXMD) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, dividends, valuation, media sentiment, analyst recommendations, institutional ownership, profitability and earnings.

13.6% of Trevena shares are owned by institutional investors. Comparatively, 4.9% of PaxMedica shares are owned by institutional investors. 2.7% of Trevena shares are owned by company insiders. Comparatively, 1.0% of PaxMedica shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

PaxMedica has lower revenue, but higher earnings than Trevena. Trevena is trading at a lower price-to-earnings ratio than PaxMedica, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Trevena$443K0.02-$40.29M-$47.04N/A
PaxMedicaN/AN/A-$18.29M-$6.09N/A

In the previous week, Trevena had 1 more articles in the media than PaxMedica. MarketBeat recorded 1 mentions for Trevena and 0 mentions for PaxMedica. Trevena's average media sentiment score of 0.37 beat PaxMedica's score of 0.00 indicating that Trevena is being referred to more favorably in the media.

Company Overall Sentiment
Trevena Neutral
PaxMedica Neutral

Trevena's return on equity of 0.00% beat PaxMedica's return on equity.

Company Net Margins Return on Equity Return on Assets
TrevenaN/A N/A -119.55%
PaxMedica N/A -3,167.89%-560.35%

Trevena has a beta of -0.55, meaning that its stock price is 155% less volatile than the broader market. Comparatively, PaxMedica has a beta of -0.99, meaning that its stock price is 199% less volatile than the broader market.

Summary

Trevena beats PaxMedica on 8 of the 11 factors compared between the two stocks.

How does PaxMedica compare to Navidea Biopharmaceuticals?

PaxMedica (NASDAQ:PXMD) and Navidea Biopharmaceuticals (NYSE:NAVB) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, institutional ownership, earnings, media sentiment, profitability, analyst recommendations, risk and valuation.

In the previous week, PaxMedica's average media sentiment score of 0.00 equaled Navidea Biopharmaceuticals'average media sentiment score.

Company Overall Sentiment
PaxMedica Neutral
Navidea Biopharmaceuticals Neutral

Navidea Biopharmaceuticals' return on equity of 0.00% beat PaxMedica's return on equity.

Company Net Margins Return on Equity Return on Assets
PaxMedicaN/A -3,167.89% -560.35%
Navidea Biopharmaceuticals N/A N/A N/A

4.9% of PaxMedica shares are held by institutional investors. Comparatively, 0.0% of Navidea Biopharmaceuticals shares are held by institutional investors. 1.0% of PaxMedica shares are held by insiders. Comparatively, 43.7% of Navidea Biopharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Navidea Biopharmaceuticals has higher revenue and earnings than PaxMedica. PaxMedica is trading at a lower price-to-earnings ratio than Navidea Biopharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
PaxMedicaN/AN/A-$18.29M-$6.09N/A
Navidea Biopharmaceuticals$8.13K0.00-$15.18M-$0.21N/A

PaxMedica has a beta of -0.99, indicating that its stock price is 199% less volatile than the broader market. Comparatively, Navidea Biopharmaceuticals has a beta of 1.76, indicating that its stock price is 76% more volatile than the broader market.

Summary

Navidea Biopharmaceuticals beats PaxMedica on 7 of the 9 factors compared between the two stocks.

How does PaxMedica compare to Genocea Biosciences?

Genocea Biosciences (NASDAQ:GNCA) and PaxMedica (NASDAQ:PXMD) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their media sentiment, valuation, institutional ownership, earnings, profitability, risk, analyst recommendations and dividends.

Genocea Biosciences has a beta of 1.61, meaning that its share price is 61% more volatile than the broader market. Comparatively, PaxMedica has a beta of -0.99, meaning that its share price is 199% less volatile than the broader market.

PaxMedica has lower revenue, but higher earnings than Genocea Biosciences. PaxMedica is trading at a lower price-to-earnings ratio than Genocea Biosciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Genocea Biosciences$1.91M0.00-$33.20M-$0.61N/A
PaxMedicaN/AN/A-$18.29M-$6.09N/A

0.6% of Genocea Biosciences shares are owned by institutional investors. Comparatively, 4.9% of PaxMedica shares are owned by institutional investors. 1.6% of Genocea Biosciences shares are owned by insiders. Comparatively, 1.0% of PaxMedica shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

In the previous week, Genocea Biosciences' average media sentiment score of 0.00 equaled PaxMedica'saverage media sentiment score.

Company Overall Sentiment
Genocea Biosciences Neutral
PaxMedica Neutral

Genocea Biosciences' return on equity of -182.88% beat PaxMedica's return on equity.

Company Net Margins Return on Equity Return on Assets
Genocea BiosciencesN/A -182.88% -62.76%
PaxMedica N/A -3,167.89%-560.35%

Summary

Genocea Biosciences beats PaxMedica on 6 of the 9 factors compared between the two stocks.

Get PaxMedica News Delivered to You Automatically

Sign up to receive the latest news and ratings for PXMD and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PXMD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

PXMD vs. The Competition

Export
MetricPaxMedicaPharmaceuticals IndustryHealthcare SectorNASDAQ Exchange
Market Cap$6K$12.53B$7.26B$13.10B
Dividend YieldN/A2.63%2.52%12.57%
P/E Ratio0.00792.39274.9825.77
Price / SalesN/A850.84679.2597.61
Price / CashN/A88.6477.8052.76
Price / Book0.0010.6910.526.34
Net Income-$18.29M$2.83B$3.49B$360.00M
7 Day PerformanceN/A-0.69%-1.08%-0.11%
1 Month PerformanceN/A-1.10%-3.39%-3.42%
1 Year PerformanceN/A2.10%15.08%5.46%

PaxMedica Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
PXMD
PaxMedica
N/A$0.00
flat		N/AN/A$6KN/AN/A6
VRPX
Virpax Pharmaceuticals
N/A$0.01
flat		N/AN/A$14KN/AN/A7
SYRS
Syros Pharmaceuticals
N/A$0.00
-96.7%		N/A+300.0%$11K$386KN/A120
TRVN
Trevena
N/A$0.01
flat		N/A+12.0%$11K$443KN/A40
NAVB
Navidea Biopharmaceuticals
N/AN/AN/AN/A$10K$8.13KN/A10

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:PXMD) was last updated on 9/24/2026 by MarketBeat.com Staff.
From Our Partners
A letter from Shannon Stansberry
Porter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down ye...
Porter & Company | Sponsoredtc pixel
They're shrinking your dollars every single month
Since 2020, the dollar has lost roughly a quarter of its buying power. A $500,000 nest egg today buys about wh...
American Alternative | Sponsoredtc pixel
Shocking new footage just released
Gerardo Del Real is calling it the Third Convergence Event, a new catalyst hitting the uranium market that he ...
Digest Publishing | Sponsoredtc pixel
The retirement stock I'd buy before Nvidia today
In 2014, Marc Chaikin pointed readers toward Nvidia. Now the 60-year Wall Street veteran and creator of the Ch...
Chaikin Analytics | Sponsoredtc pixel
CODE RED: AI Meltdown Imminent?
After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...
Paradigm Press | Sponsoredtc pixel
NASA's ISS Replacement Could Go to This Tiny Space Firm
NASA has commissioned SpaceX to decommission the $150 billion International Space Station, but the contract to...
Behind the Markets | Sponsoredtc pixel
Bank of America: 'Digital Dollar Inevitable'
Bank of America just revealed your expiration date. In their Bloomberg interview, they didn't just predict the...
Decentralized Masters | Sponsoredtc pixel
Your book attached
Bill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...
Profits Run | Sponsoredtc pixel